Results of cause-specific Cox regression analysis for relapse after 2 induction cycles and at EOT
| Variable . | BM . | PB . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| After 2 induction cycles . | At EOT . | After 2 induction cycles . | At EOT . | |||||||||
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| Randomizationto GO-Arm | .58 | .39-.84 | .004 | .63 | .4-1.00 | .05 | .79 | .54-1.16 | .23 | .62 | .38-1.02 | .057 |
| MRDposin BM | 1.82 | 1.01-3.26 | .04 | 2.41 | 1.55-3.77 | .0001 | 3.12 | 2.04-4.79 | <.0001 | 5.50 | 3.44-8.79 | <.0001 |
| FLT3-ITDpos (AR ≥ .5) | 2.17 | 1.13-4.18 | .02 | 2.36 | 1.03-5.44 | .04 | 2.41 | 1.17-4.94 | .016 | 3.06 | 1.38-6.80 | .005 |
| FLT3-TKDmut | 1.19 | .68-2.08 | .53 | .91 | .49-1.7 | .77 | .80 | .43-1.52 | .49 | .69 | .34-1.41 | .31 |
| DNMT3Amut | 2.73 | 1.72-4.34 | <.0001 | 2.14 | 1.29-3.53 | .003 | 3.01 | 1.86-4.89 | <.0001 | 3.27 | 1.85-5.80 | <.0001 |
| Age* | 1.48 | 1.25-1.76 | <.0001 | 1.51 | 1.24-1.85 | <.0001 | 1.52 | 1.28-1.82 | <.0001 | 1.31 | 1.06-1.62 | .01 |
| WBC† | .98 | .72-1.33 | .89 | .94 | .66-1.33 | .71 | .98 | .73-1.31 | .88 | .94 | .68-1.31 | .73 |
| LDH† | 1.86 | .84-4.14 | .12 | 1.62 | .67-3.9 | .28 | 1.64 | .67-3.99 | .27 | 1.12 | .45-2.81 | .80 |
| BM blasts | .99 | .99-1.00 | .07 | .99 | .98-1.00 | .15 | .99 | .98-1.00 | .08 | 1.00 | .99-1.01 | .83 |
| Variable . | BM . | PB . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| After 2 induction cycles . | At EOT . | After 2 induction cycles . | At EOT . | |||||||||
| HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | HR . | 95% CI . | P . | |
| Randomizationto GO-Arm | .58 | .39-.84 | .004 | .63 | .4-1.00 | .05 | .79 | .54-1.16 | .23 | .62 | .38-1.02 | .057 |
| MRDposin BM | 1.82 | 1.01-3.26 | .04 | 2.41 | 1.55-3.77 | .0001 | 3.12 | 2.04-4.79 | <.0001 | 5.50 | 3.44-8.79 | <.0001 |
| FLT3-ITDpos (AR ≥ .5) | 2.17 | 1.13-4.18 | .02 | 2.36 | 1.03-5.44 | .04 | 2.41 | 1.17-4.94 | .016 | 3.06 | 1.38-6.80 | .005 |
| FLT3-TKDmut | 1.19 | .68-2.08 | .53 | .91 | .49-1.7 | .77 | .80 | .43-1.52 | .49 | .69 | .34-1.41 | .31 |
| DNMT3Amut | 2.73 | 1.72-4.34 | <.0001 | 2.14 | 1.29-3.53 | .003 | 3.01 | 1.86-4.89 | <.0001 | 3.27 | 1.85-5.80 | <.0001 |
| Age* | 1.48 | 1.25-1.76 | <.0001 | 1.51 | 1.24-1.85 | <.0001 | 1.52 | 1.28-1.82 | <.0001 | 1.31 | 1.06-1.62 | .01 |
| WBC† | .98 | .72-1.33 | .89 | .94 | .66-1.33 | .71 | .98 | .73-1.31 | .88 | .94 | .68-1.31 | .73 |
| LDH† | 1.86 | .84-4.14 | .12 | 1.62 | .67-3.9 | .28 | 1.64 | .67-3.99 | .27 | 1.12 | .45-2.81 | .80 |
| BM blasts | .99 | .99-1.00 | .07 | .99 | .98-1.00 | .15 | .99 | .98-1.00 | .08 | 1.00 | .99-1.01 | .83 |
AR, allelic ratio; HR, hazard rate; LDH, lactate dehydrogenase; MRDpos, MRD positivity; TKD, tyrosine kinase domain; WBC, white blood cell count.
MRD status was determined at the respective time point; FLT3-ITD and FLT3-TKD mutation status, DNMT3A mutation status, BM blasts, age, serum LDH, and WBC count were determined at diagnosis.
Increase of 10 years of age.
Log10-transformed continuous variables.